News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–79
Matches
79
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

79 matching headlines

Ticker or company: NOVOBNMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Market update Main company 🇲🇽 Mexico

Pharma heavyweights clash over anti-obesity drug ads

Anti-obesity treatments have been a financial windfall for Novo Nordisk and Eli Lily (SEBASTIEN BOZON) Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

Novo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospital

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇲🇽 Mexico

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company's obesity franchise across Europe, making Wegovy …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA CAMBRIDGE, Mass., July 20, …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇲🇽 Mexico

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇲🇽 Mexico

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The European Commission approved Novo Nordisk A/S' Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related …

NOVOBN main company
Sharemaestro market context Trend signal started 52 weeks -24.4% · Next-week setup negative 40.6% NOVOBN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context